RxDoctor Payments Data

Samuel Myrick, MD

Internal Medicine · Ocala, FLNPI 1831180546

Payments from drug & device makers

$115,536in general payments, 2019–2025

Across 1,377 payments — averaging $83.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$40K
  • Incyte Corporation$34K
  • Janssen Research & Development, LLC$7K
  • E.r. Squibb & Sons, L.L.C.$5K
  • Merck$3K
  • Novartis$3K
  • plus $23K from 54 others
$3,965in research payments, 2019–2025

Across 1 payment — averaging $3965.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bristol Myers Squibb$4K

What the payments were for

  • Food & beverage$27,40591%
  • Education$1,5255%
  • Other$1,1804%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bristol Myers Squibb72$39,524
Incyte Corporation47$33,977
Janssen Research & Development, LLC1$7,000
E.r. Squibb & Sons, L.L.C.58$5,039
Merck60$3,194
Novartis102$2,760
Seagen Inc.43$1,938
AstraZeneca(2 entities)77$1,793
Pfizer76$1,692
Johnson & Johnson91$1,668
Astellas Pharma US Inc44$1,064
Amgen55$1,052
Daiichi Sankyo Inc.35$712
Gilead(2 entities)32$693
GSK35$675
Bayer30$662
Jazz Pharmaceuticals Inc.24$584
Lilly USA, LLC45$565
Sanofi25$557
Eisai Inc.27$551
Genmab U.S., Inc.10$534
Genentech USA, Inc.31$528
Regeneron Healthcare Solutions, Inc.18$514
Takeda Pharmaceuticals U.S.A., Inc.18$457
Pharmacyclics LLC, An Abbvie Company19$450
EMD Serono, Inc.19$430
Ipsen Biopharmaceuticals, Inc8$369
Servier Pharmaceuticals LLC18$363
Puma Biotechnology, Inc.11$333
Rigel Pharmaceuticals, Inc.14$297
Octapharma USA, Inc.5$295
Array Biopharma Inc15$282
AbbVie13$226
Boehringer Ingelheim9$194
Karyopharm Therapeutics Inc.9$191
Novocure Inc.5$185
Janssen Scientific Affairs, LLC3$183
Stemline Therapeutics Inc.6$176
Pharmaessentia USA Corporation8$169
Mirati Therapeutics, Inc.8$164
Tersera Therapeutics LLC8$154
Taiho Oncology, Inc.7$150
G1 Therapeutics, Inc.7$137
Caris MPI, Inc.1$131
Beigene USA, Inc.7$131
Fennec Pharmaceuticals, Inc.6$130
Dendreon Pharmaceuticals LLC4$128
Pharmacosmos Therapeutics Inc.6$127
Dova Pharmaceuticals2$126
Agios Pharmaceuticals, Inc.6$123
Morphosys, US Inc.5$117
Foundation Medicine, Inc.4$117
Clovis Oncology, Inc.1$116
AVEO Pharmaceuticals, Inc.6$105
Menarini Silicon Biosystems, Inc.1$102
CTI Biopharma Corp.5$97
Deciphera Pharmaceuticals Inc.5$92
Sun Pharmaceutical Industries Inc.3$88
TG Therapeutics, Inc.2$87
Apellis Pharmaceuticals, Inc.4$83

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$115,536 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$3,437,369
Medicare patients
727
Services billed
175,661

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide20$372,462
ImbruvicaIbrutinib21$337,587
LenvimaLenvatinib Mesylate12$291,709
XtandiEnzalutamide13$182,919
Lenalidomide19$157,992
Abiraterone Acetate47$41,656
EliquisApixaban36$29,163
XareltoRivaroxaban33$27,634
Anastrozole129$3,488
Tamoxifen Citrate39$1,885
Hydroxyurea25$952
Dexamethasone58$801
Letrozole30$748
Gabapentin26$424
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen22$363

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada, Xarelto$1,668$400,09653 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$450$337,58721 claims
Eisai Inc.Lenvima$551$291,70912 claims
Astellas Pharma US IncXtandi$1,064$182,91913 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$183$41,65647 claims
PfizerEliquis$1,692$29,16336 claims
Lilly USA, LLCOlanzapine$565$9018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Ocala

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →